000			03965nam a22005655i 4500
001			978-3-031-65948-5
003			DE-He213
005			20251030114638.0
007			cr nn 008mamaa
008			241225s2024 sz | s |||| 0|eng d
020			_a9783031659485 _9978-3-031-65948-5
024	7		_a10.1007/978-3-031-65948-5 _2doi
050		4	_aQH323.5
072		7	_aPBT _2bicssc
072		7	_aMED090000 _2bisacsh
072		7	_aPBT _2thema
245	1	0	_aBiostatistics in Biopharmaceutical Research and Development _h[electronic resource] : _bClinical Trial Design, Volume 1 / _cedited by Ding-Geng Chen.
250			_a1st ed. 2024.
264		1	_aCham : _bSpringer Nature Switzerland : _bImprint: Springer, _c2024.
300			_aXXIV, 344 p. 118 illus. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aBias and Randomization in Clinical Trials: 1980s – 2020s – 2060s -- The Markov Model for Survival Trials at 35 Years-Old -- Absolute Power Corrupts Absolutely: A Review of the Use of Unconditional Probabilities in the Planning of Clinical Trials -- Design of Clinical Trials with the Desirability of Outcome Ranking Methodology -- Benefit:Risk Assessments during Clinical Trials: A Prediction Approach Using the Desirability of Outcome Ranking (DOOR) -- The Power of Integration: How the 2-in-1 Clinical Trial Design is Changing the Future of Drug Development -- A Unified Bayesian Decision Rule-Based Approach for Bayesian Design of Clinical Trials Using Historical Data -- Group Sequential Design Under Non-proportional Hazards: Methodologies and Examples -- Multiple Testing in Group Sequential Design -- Plan per-protocol (PP) causal inference analysis addressing intercurrent events following the targeted learning roadmap -- Maximum Tolerated Imbalance Randomization: Theory and Practice -- Response-adaptive randomization designs based on optimal allocation proportion.
520			_aThe Deming Conference on Applied Statistics has long been deemed an influential event in the biostatistics and biopharmaceutical profession. It provides learning experience on recent developments in statistical methodologies in biopharmaceutical applications and FDA regulations. This book honors 80 years of contributions and dedication of the Deming Conference in biostatistics, and biopharmaceutical clinical trial methodology and applications. All chapters are contributed by world-class and prominent Deming speakers, who've contributed their cutting-edge research and developments to the community. Volume 1 covers Historical Milestones in Clinical Trial Design, FDA biopharmaceutical design guidance, and emerging development in Clinical Trial Design Methodology. This book aims to booster research, education, and training in biostatistics and in biopharmaceutical research and development.
650		0	_aBiometry. _965981
650		0	_aClinical medicine _xResearch. _974123
650		0	_aPublic health. _961312
650		0	_aSampling (Statistics). _959805
650		0	_aData mining. _96941
650	1	4	_aBiostatistics. _965985
650	2	4	_aClinical Research. _974124
650	2	4	_aPublic Health. _961312
650	2	4	_aSurvey Methodology. _974358
650	2	4	_aData Mining and Knowledge Discovery.
700	1		_aChen, Ding-Geng. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt _980220
710	2		_aSpringerLink (Online service)
773	0		_tSpringer Nature eBook
776	0	8	_iPrinted edition: _z9783031659478
776	0	8	_iPrinted edition: _z9783031659492
776	0	8	_iPrinted edition: _z9783031659508
856	4	0	_uhttps://doi.org/10.1007/978-3-031-65948-5
912			_aZDB-2-SME
912			_aZDB-2-SXM
999			_c66021 _d66021